Hippo Pathway in Cancer, towards Realization of the Hippo-Targeted Therapy

Message from the Guest Editor

Dear Colleagues,

The Hippo pathway is the newest and possibly be the last addition to signalling pathways, which have ever been growing. We know now that the fundamental role of the pathway is the negative regulation of two transcription regulators, YAP1 and TAZ. YAP1/TAZ co-operate with TEAD and other transcription factors to regulate cell proliferation and differentiation.

Human cancers are frequently associated with deregulation of the Hippo pathway. The consequent hyperactivation of YAP1/TAZ and TEAD induces epithelial-mesenchymal transition and enhances drug resistance. Accordingly, the incidence of metastasis and recurrence is increased. It is reasonable to assume that inhibition of YAP1/TAZ and TEAD improves prognosis in cancer patients. This Special Issue will highlight a part of the efforts of researchers towards the realization of Hippo-targeted therapy and provide a forum for brainstorming.

Prof. Yutaka Hata
Guest Editor

mdpi.com/si/10967
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 5.87, which equals rank 26/321 (Q1) in 'Oncology' and rank 24/191 (Q1) in 'Cancer Research'.

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI